Evidence map›Paper›PMID 25671063›Full record

ArticleNutrition research and practice2015

Inhibitory effect of Erythronium japonicum on the human breast cancer cell metastasis.

Mi-Kyoung You, Min-Sook Kim, Jin Rhyu, Mi-Ae Bang, Hyeon-A Kim

Open access · hybridAbstract read
In one paragraph

Article in Nutrition research and practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Antioxidants (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mi-Kyoung YouDepartment of Food & Nutrition / Research Institute of Human Ecology, Mokpo National University, 1666, Yeongsan-ro, Cheonggye-myeon, Muan-gun, Jeonnam 534-729, Korea.
Min-Sook KimNature Pure Korea Inc. Jeonnam 517-803, Korea.
Jin RhyuDepartment of Food & Nutrition / Research Institute of Human Ecology, Mokpo National University, 1666, Yeongsan-ro, Cheonggye-myeon, Muan-gun, Jeonnam 534-729, Korea.
Mi-Ae BangJeonnam Biofood Technology Center, Jeonnam 520-330, Korea.
Hyeon-A KimDepartment of Food & Nutrition / Research Institute of Human Ecology, Mokpo National University, 1666, Yeongsan-ro, Cheonggye-myeon, Muan-gun, Jeonnam 534-729, Korea.
Mokpo National University · KRJeonnam Bioindustry Foundation · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesIn this study, the inhibitory effect of Erythronium japonicum extracts on the metastasis of MDA-MB-231 human breast cancer cell line was determined. MATERIALS/

methodsCells were cultured with DMSO or with 50, 75, 100 or 250 µg/ml of Erythronium japonicum methanol or ethanol extract.

resultsBoth methanol and ethanol extracts significantly inhibited the growth and induced apoptosis of MDA-MB-231 cells in a dose-dependent manner. Erythronium japonicum extracts inhibited the adhesion of MDA-MB-231 cells. The invasion of breast cancer cells was suppressed by Erythronium japonicum extracts in a dose-dependent manner. The motility and MMP-2 and MMP-9 activities were also inhibited by both methanol and ethanol extracts.

conclusionsOur results collectively indicate that Erythronium japonicum extracts inhibit the growth, adhesion, migration and invasion as well as induce the apoptosis of human breast cancer cells. Clinical application of Erythronium japonicum as a potent chemopreventive agent may be helpful in limiting breast cancer invasion and metastasis.

Indexed as

apoptosiscancerErythronium japonicuminvasionproliferation

Identifiers

PMID25671063
PMCPMC4317474
OpenAlexW2106747063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.